FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)
NCT01524705 on ClinicalTrials.gov · last registry update 2023-12-29
Finished July 2014, after enrolling 102 people. Primary outcome, as filed: Coefficient of Variation at 26 Weeks Minus Coefficient of Variation at Baseline. exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- COMPLETED
- Phase
- P4
- Drug
- exenatideBydureon, Byetta
- Sponsor
- University of Washington
- Sponsor type
- Other
- Enrollment
- 102
- Started
- 2012-08
- Primary completion
- 2014-07 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Coefficient of Variation at 26 Weeks Minus Coefficient of Variation at Baseline
Conditions studied
Type 2 Diabetes
Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.